Loading Suven Life Sciences…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 4 | 2 | 3 | 1 | 2 |
| Operating profit | -135 | -52 | -105 | -81 | -52 |
| Operating margin | -3776.4% | -3435.0% | -3727.6% | -8821.6% | -2791.9% |
| Net profit | -128 | -46 | -102 | -77 | -52 |
| Net margin | -3578.7% | -2999.5% | -3628.8% | -8410.6% | -2759.8% |
| EPS (₹) | -4.84 | -2.02 | -4.55 | -3.48 | -2.36 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 7 | 7 | 12 | 14 |
| Operating profit | -290 | -171 | -134 | -132 |
| Operating margin | -4072.2% | -2572.9% | -1148.5% | -974.3% |
| Net profit | -276 | -161 | -105 | -118 |
| Net margin | -3884.1% | -2415.1% | -898.6% | -873.5% |
| EPS (₹) | -12.13 | -7.37 | -4.82 | -6.63 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 624 | 135 | 285 | 389 |
| Total liabilities | 33 | 25 | 15 | 14 |
| Shareholders’ equity | 591 | 110 | 270 | 375 |
| Total debt | 17 | 0 | 1 | 2 |
| Cash & equivalents | 8 | 15 | 15 | 37 |
| Debt / equity | 0.03 | 0.00 | 0.00 | 0.00 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -301 | -154 | -83 | -116 | — |
| Capital expenditure | -5 | -37 | — | -3 | -20 |
| Free cash flow | -306 | -191 | -83 | -119 | — |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | -46.7% | -146.1% | -38.9% | -31.5% |
| Return on assets | -44.3% | -118.9% | -36.9% | -30.4% |
| Net margin | -3884.1% | -2415.1% | -898.6% | -873.5% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for SUVEN. Finnhub coverage is limited for some India-listed stocks.